


**A CRO FOR
PRECLINICAL
SERVICES IN
ONCOLOGY**




OUR STRENGTHS





OUR VERSATILITY

The reactivity, adaptability and flexibility of a human-sized company.



OUR PERSONALIZED ADVICE

A Scientific Advisory Board of clinical experts to understand your needs and projects.



SECONDARY RESISTANCE MODELS

Secondary resistance models to standards of care established and characterized through RNAseq and immunophenotyping of the tumor microenvironment.



OUR COMPETITIVE PRICES

To provide our customers with excellent value for money compared to the competition.

ABOUT US



Spin-off of the Team Anticancer Antibodies Centre de Recherche en Cancérologie (CRCL)

Company

CRO created in May 2015,
specialized in proof-of-
concept studies in oncology




Team

Scientists and efficient team
recognized for its expertise in
onco-pharmacology at the
international level

Location

BioParc Rockefeller
Bâtiment BIOSERRA 2
Lyon



Customers

French and international
clients composed of
pharmaceutical,
biotechnology companies
and academic institutions



Track-record

- CIR agreement 2020-2025
- Fully authorized animal
house and personnel

- 200+ studies
- 40 sponsors
- 6 ongoing partnerships



January 2025

Corporate presentation

OUR TEAM





Renaud Marin-Sidgwick
CEO



Charles Dumontet, MD-PhD
CSO - Consultant



Marie Tautou, PhD
Study Director
Head of Business Development



Charline Perrouin
Business Development Manager
Head of Communications



Doriane Mathé
Study Manager



Pierre-Antoine Choffour
Study Manager



Marine Fellmann
Study Manager



Jean-Philippe Druet
Executive Assistant



Mickaël Zergane
Study Assistant



Jade Ruard
Study Assistant



Stecy Chhor
Study Assistant



Aurélie Cadiou
PhD student



Flore Sarraute
Apprentice



January 2025


Corporate presentation

THERAPEUTIC AREAS



Oncology and immuno-oncology

Small molecules




Biological molecules

Antibodies, peptides



Cellular and gene therapies



OUR SERVICES




Antineo's services



Optimize and accelerate
the development of our
customers' compounds

**Provide advice, expertise
and services**



IN VITRO SERVICES



Cytotoxicity assays



Determination of IC50 / EC50

Synergy / Antagonism assay


Colorimetric
method

MTT

MTS


Cell Titer-
Glo®

Luminescence
method



Cell viability / Cell metabolic activity /
Cytotoxicity / Cell proliferation

mAb Cytotoxicity (MDA-MB-231)



Continuous-monitoring studies



Realize a real-time analysis of a variety of cellular and immunological processes

IncuCyte

Cytotoxicity with specific reagents

Proliferation, with or without fluorescence

Antibody internalisation

Apoptosis, by Caspase-3/7 or Annexin V labelling

Migration & invasion (wound healing)

Phagocytosis

Immune cell, proliferation, clustering and killing (CTL and ADCC)

Other custom applications

xCELLigence


Cytotoxicity

Immune cell killing (CTL and ADCC)

Phagocytosis

Migration & invasion


Other custom applications



January 2025

Corporate presentation

Characterisation of samples



January 2025

Corporate presentation



Flow Cytometry - (FACS)






Qualitative and quantitative
multiparametric analyses

BD FACS CANTO™

Classical

3 lasers : 8 markers* maximum



LSR FORTessa™

Classical

4 lasers : 18 markers* maximum

CYTEK

Spectral

5 lasers : up to 29 markers*

EX VIVO SERVICES



Immunology services



Isolate the cells of interest and characterise your target molecule by Flow Cytometry



Partnership

- **Analysis on fresh samples** : on blood products (blood bags) and by products (buffy coat)
- Most assays can be performed as **end point** and **continuous-monitoring** studies

T cell based assays



Myeloid Cells based assays



ADCC assays with fresh NK cells



ADCP assays with fresh myeloid cells



January 2025


Corporate presentation

Development of immunotherapies



Highlight the target and decipher the mechanisms of action of therapeutic antibodies

- **Immunology ex vivo assays** (T cell activation by IFN γ measurements, CTL assays, Macrophage polarisation etc.)
- In vitro or ex vivo **ADCC, ADCP and CDC assays** (calcein release)
- Original methods for **in vivo assessment of ADCC and CDC activities**
- Titration / Internalization / By-stander effect (ADC) ...
- Original in vitro and in vivo assays for **bispecific antibodies** (anti-CD3)
- A unique panel of tumour models presenting **secondary resistances to immunotherapies**



IN VIVO SERVICES



Animal facilities

- **High standards facility** with strictly controlled environment
- **Multiple types of experiments** : study cancer progression, assess the effectiveness and innocuity of novel therapies,...
- **Wide range of animal models** from immune-competent (C57Bl/6, CD1...) to immune-deficient (SCID-CB17, NSG, NOG, NOD-SCID...) and **humanized models** (BRGSF-HIS, huNOG-EXL)
- **Capacity over 3,000 mice**
- **Ethical compliance and expertise in animal experimentation**



Standard of care therapies

- As reference for the tested compound
- For comparison studies
- For combination / synergy studies

Choice of tumor models

- 100+ cell-derived xenograft models
- 40 murine syngeneic models for immuno-oncology
- Subcutaneous or orthotopic implantation

01

02

Protocol adapted to our clients' compounds

- Route (IV / IP / PO / IT)
- Galenic formulations (liposome encapsulation)
- Schedule of injection
- Schedule and duration of follow-up
- Weekly updates
- Choice of end-point (with control or individual ethical end-points)

03

January 2025

Corporate presentation




In vivo analysis



Demonstrate the antitumor activity of a novel agent in animal models, as well as defining the dosage and schedule that is both efficient and non-toxic



Recommendations on the choice of the best indication and model



Systemic and haematological toxicity of your compounds in rodents (VetScan / MS9)



Pharmacokinetics properties in mouse and rat



Antitumor efficacy in human or mice tumour models



Combination / comparison with gold standards



Orthotopic models*



Immunophenotyping of the tumour micro environment



An original offer of secondary resistances to reference therapies (CDX and syngeneic)



The development of models of resistance


*[In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1/PD-L1 Therapies](#)




ORIGINAL RESISTANT TUMOR MODELS



Acquired resistance to anti-PD(L)1



Our established resistance models



*In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1/PD-L1 Therapies

January 2025

Corporate presentation



CDX Models

Lymphoma

- Follicular Lymphoma - (RL model) :
- *Rituximab / GA101 / R-CHOP / R-DHAP*
- Mantle Cells Lymphoma - (Granta model) :
- *Rituximab*
- Diffuse large B cells lymphoma - (Toledo model) :
- *Rituximab*
- Burkitt's lymphoma
- Raji model : *Rituximab*
 - Daudi model : *CAL-101*

Myeloma

- Plasma cells myeloma RPMI8226 model
- *Daratumumab*
- Multiple myeloma MM.1S
- *Daratumumab*

Breast


- Tubular Adenocarcinoma BT474
- *T-DM1*
- MDA-MB-361 model
- *Trastuzumab T-DM1*

Colorectal / Gastric

- Gastric carcinoma NCI-N87
- *Trastuzumab*

Bespoke services : On demand development of resistant models (Syngeneic or CDX models)

Syngeneic Models



CDX Models

Syngeneic Models

Lymphoma

- Follicular Lymphoma - (RL model) :
- Rituximab / GA101 / R-CHOP / R-DHAP)
- Mantle Cells Lymphoma - (Granta model) :
- Rituximab
- Diffuse large B cells lymphoma - (Toledo model) :
- Rituximab
- Burkitt's lymphoma
- Raji model : Rituximab
 - Daudi model : CAL-101

Myeloma

- Plasma cells myeloma RPMI8226
- Daratumumab
- Multiple myeloma MM.1S
- Daratumumab

Breast

- Tubular Adenocarcinoma BT474
- T-DM1
- MDA-MB-361 model
- Trastuzumab T-DM1

Colorectal / Gastric

- Gastric carcinoma NCI-N87
- Trastuzumab

Bespoke services : On demand
development of resistant models
(Syngeneic or CDX models)

Colon

- MC38 model
- anti-PD1 / anti-PDL-1

Bladder

- MBT-2 model
- anti-PD1
- MB49 model
- anti-PD1 / anti-PDL-1

Kidney

- RENCA model
- anti-PD1 / anti-PDL-1

Melanoma


- B-raf
- anti-PD1 / anti-PDL-1
- N-Ras
- anti-PD1 / anti-PDL-1
- Tyr N-Ras models
- anti-PD1 / anti-PDL-1

BRAND NEW : Pancreas

- Kic8 model
- PD1 / PDL1 / Gemcitabine

Lymphoma

- P388 model
- anti-PD1 / anti-PDL-1



Partner platforms



CIOLE

Microscopy platform for
Immunohistochemistry
(IHC)



**PROFIL
EXPERT**

High throughput
sequencing,
microdissection and
single cell technologies

HawkCell

HAWKCELL

Platform for Magnetic
Resonance Imaging
(MRI)



IMTHERNAT

PET-Scan
(Radiolabelling)



ANAQUANT

Detection and
quantification of
proteins by mass
spectrometry



**PAREAN
BIOTECHNOLOGIES**

Immune omics analysis
(Single cell)



January 2025


Corporate presentation

OUR NEWS




IVIS® Lumina Series III Imager


MDA-MB-231 cell line




2023-04-05



2023-04-12



2023-04-26



- **In vivo and 2D imaging of the tumors/metastasis**
- **Precise tumor monitoring and follow-up**
- **Animal saving**
- **Biodistribution and efficacy studies**



Hepatic metastases of an
MDA-MB-231 Luciferase
(+) model by intrasplenic
implantation





January 2025

Corporate presentation

3D Bioprinting - *Ongoing development*

BT 474-GFP cell line



- Recapitulate the tumor microenvironment - (TME)
- High-throughput screening
- Minimising animals used and costs



January 2025


Corporate presentation

CASE STUDIES




Efficacy study


MCF-7 tumor growth







Hs746T tumor growth




KIC8 Gemcitabine-resistant tumor growth




Toxicity study – Haematological analysis



mAb Titration assay (SK-BR3)



mAb Internalization assay (SK-BR3)



THEY TRUST US!



EVEXTA BIO

SAYENS
SATT
CATALYSEUR D'INNOVATIONS

Yomi
PHARMA

mablink

ad advanced
biodesign

Stroma Care

Roche

Breach Bio

CASINVENT

GAMA MABS
PHARMA

Jalon
THERAPEUTICS

PULSALYS

CRCCL
CENTRE DE
RECHERCHE EN
CANCEROLOGIE
DE LYON

Antineo

January 2025

Corporate presentation

THANK YOU!



(+33) 4 72 36 15 71



www.antineo.fr



ANTINEO

2e étage - Bâtiment BIOSERRA 2

60F avenue Rockefeller

69008 LYON



[Antineo](#)

